Targeting to 5-HT1F Receptor Subtype for Migraine Treatment: Lessons from the Past, Implications for the Future

E-ISSN： 1875-6166|12|4|241-249

ISSN： 1871-5249

Source： Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Central Nervous System Agents), Vol.12, Iss.4, 2012-12, pp. : 241-249

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Pharmacokinetics of Almotriptan, a Serotonin 5-HT 1B/1D Receptor Agonist for the Treatment of Migraine

By McEnroe Janet D. Fleishaker Joseph C.

Clinical Pharmacokinetics, Vol. 44, Iss. 3, 2005-01 ,pp. : 237-246

Adis International

Access to resources Recommend Favorite

Rizatriptan: a new 5-HT_1B/1D receptor agonist for the treatment of migraine

By Dahlof C. Lines C.

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 5, 1999-05 ,pp. : 671-685

Informa Healthcare

Access to resources Recommend Favorite

5HT1F- and 5HT7-Receptor Agonists for the Treatment of Migraines

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 6, Iss. 4, 2007-08 ,pp. : 235-237

Bentham Science Publishers

Access to resources Recommend Favorite

Is the 5-HT 7 receptor involved in the pathogenesis and prophylactic treatment of migraine?

By Terron J.A.

European Journal of Pharmacology, Vol. 439, Iss. 1, 2002-03 ,pp. : 1-11

Elsevier

Access to resources Recommend Favorite

Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine

By Bou J. Domenech T. Puig J. Heredia A. Gras J. Fernandez-Forner D. Beleta J. Palacios J.M.

European Journal of Pharmacology, Vol. 410, Iss. 1, 2000-12 ,pp. : 33-41

Elsevier

Access to resources Recommend Favorite